Blood

Article	Citations
Warthin-Finkeldey cells seen in a setting other than measles: chronic lymphocytic leukemia/small lymphocytic lymphoma	2662
Stem Cell Autograft Minimal Residual Disease Negativity Improves Outcomes after Autotransplant for Multiple Myeloma	2413
Hemophagocytic Lymphohistiocytosis Clinical Features and Outcomes: Single Institution Case Series	1343
Development of a Fast and Quantitative FLT3-TKD Mutation Prototype Using Lab in a Cartridge™ Technology	348
SDC2 Expression Is Increased in Myeloma Cells in Response to Loss of Pro-Survival Surface Proteins, CD28 and CD86	283
Impact of Chronic Disease and Its Burden on Aspects of Quality of Life in a Unique Sub-Population of Myeloproliferative Neoplasm Patients	226
Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML	222
Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma	220
Impacts of the COVID-19 Pandemic on Assessment of M-Protein and Free Light Chain Levels in Patients with Multiple Myeloma	201
A-two to the rescue	194
Collins PJ, Fox CP, George L, et al. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. Blood. 2021;137(2):203-215.	193
Germline Variants in MDM4 Cause a Disorder of p53 Dysregulation and Insufficient Telomere Maintenance	190
The chromatin accessibility landscape of pediatric AML	185
A New Class of Synthetic Type-B Polycyclic Polyprenylated Acylphloroglucinols (PPAP-B) Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia (AML)	182
Contactless edema via plasmin	179
Waking up exhausted BCMA-specific T cells in myeloma	170
Heparin or nonheparin anticoagulants for VITT	163
MDM2 inhibition augments GVL effect	157
Blast phagocytosis	148
High-mobility-group protein A1 in MPN progression	147
An AID to follicular lymphoma transformation	145
Unexpected parvovirus B19 infection in a patient with multiple myeloma	143
PI3king apart a rare disease with targeted therapy	142
Bleeding tendency with corkscrew hair	142
Peripheral erythrophagocytosis in paroxysmal cold hemoglobinuria	141

Breaking T-cell tolerance in the immune system	140
A rare glimpse of Fessas bodies in a patient with β-thalassemia major postsplenectomy	140
Targeting PKCα decreases iron overload in diabetes	139
A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders	137
C1 Inhibitor Deficiency Results in Increased Activation of Coagulation and Enhanced Venous Thrombosis	136
Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience	134
Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma	134
The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway	134
Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide	129
Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology	129
Treatment Patterns and Outcomes in Adolescent and Young Adults with Nodular Lymphocyte Predominant Hodgkin Lymphoma: An Impact Cohort Population-Based Study	128
Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?	127
The Role of N-Acetylcysteine Amide (NACA) As Prophylactic Treatment for Acute Graft-Versus-Host Disease	126
Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy	124
Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma	123
Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study	123
Antiviral Response and HIV-1 Inhibition in Sickle Cell Disease	120
Profiling the E3 Ubiquitin Ligase Landscape in Normal and Sickle Red Blood Cells	119
Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study	118
White Matter Injury in Sickle Cell Mice Is Associated with Reduced Neurocognitive Function and Activation of Astrocytes	118
A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation	116
Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy	116
Perception of Marijuana Use, Risk/Benefits in Sickle Cell Disease	112
Derivation and External Validation of Clinical Risk Assessment Model for Cancer Associated Thrombosis in Two Unique U.S. Healthcare Systems	112
No Specific Factors Associated with Risk of Readmission for Rebound Pain in Children with Sickle Cell Disease and Asthma Treated with Systemic Corticosteroids	111
Changes in the T Helper Cell Compartment during Treatment with the BTK Inhibitor Acalabrutinib	110
Suppressed Expression of ASCT1 Contributes to the Maintenance of Leukemia Stemness Via the Enhancement of Antioxidant Capacity	110
Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma	110
Changes in Symptoms, Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents	107
P-Selectin Blockage Potentiates the Inhibiting Effects of Inflammasome Cytokine Neutralization on Leukocyte Recruitment in an In Vivo Model of Acute Sickle Cell Vaso-Occlusion	105
Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population	105
Reticulocytes Are an Unappreciated Risk Factor for RBC Alloimmunization at the Donor and Recipient Levels	103
Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry	102
The Novel Nano-Formulation of the HDAC Inhibitor, Romidepsin, for the Treatment of Relapsed, Refractory Peripheral T-Cell Lymphoma	100
Proteotranscriptomic Strategy to Discover Acute Myeloid Leukemia Immunotherapy Targets	100
Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II Trial	98
Profiling of Heparin-Induced Thrombocytopenia Antibodies in Thai People Who Received ChAdOx1 Ncov-19 Vaccination	97
Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Ther	97
Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo	96
Genomic Landscape of IgM MGUS and Asymptomatic Waldenström Macroglobulinemia Patients	94
Analysis of Liquid Biopsy Performance for the Detection of Lymphoma in Dogs with a Focus on Recurrent Copy Number Variants in Matched Plasma and Lymph Node Aspirates: Implications for a Comparative On	94
Risk of Intracranial Hemorrhage with Direct Oral Anticoagulants (DOACs) Versus Low Molecular Weight Heparin (LMWH) in Primary and Secondary Brain Cancers: An up-to-Date Meta-Analysis of Comparative St	94
Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country	91
Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma	90
Dominant-Negative VPS4A Mutations Causing Congenital Dyserythropoietic Anemia Disrupt Iron Trafficking of Terminal Erythropoiesis	90
The Profiling of Circulating Tumor DNA Liquid Biopsy in Children and Adolescent Lymphoblastic Lymphoma	90
Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes	89
The Expression of SREBF1 Inducing By Dexamethasone Promotes Bone Marrow Mesenchymal Stromal Cells Differentiate to Adipocytes to Attract and Protect the Residual T-Cell Acute Lymphoblastic Leukemia Ce	88
Characterization of the Human Mesenchymal Stromal Compartment in Normal Homeostasis and Acute Myeloid Leukemia at the Level of the Single Cell	88
Cellular Therapy Product Viability during Long Term Cryopreserved Storage	87

Empagliflozin Modifies Neutrophils' Subsets in Patients with Glycogen Storage Disease Type Ib By Increasing Mature Neutrophils and Decreasing Immature Neutrophils	87
CRISPR-Cas9 Genome Editing of Primary Chronic Lymphocytic Leukemia Cells	87
Safety, Tolerability, and Pharmacokinetic Profile of Single and Multiple Ascending Doses of GB5121, a CNS-Penetrant BTK Inhibitor, in Healthy Subjects	86
Values and Preferences Towards Antithrombotic Therapy in Patients with Myeloproliferative Neoplasms: A Qualitative Study	86
Interim PET-CT Scan to Improve Risk Modeling for Patients with Extranodal Natural Killer/T-Cell Lymphoma Treated with Non-Anthracycline Containing L-Asparaginase Based Regimen	86
Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation	85
Identification of Biomarkers As Predictors of Patient-Reported Outcomes in Persons with Multiple Sclerosis Given Autologous Hematopoietic Stem Cell Transplantation	85
Impact on Survival of the Introduction of New Therapies for Relapsed-Refractory Aggressive B-Cell Lymphoma, Based on the Relinf Registry: A Study By the Spanish Geltamo Group	83
A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic	82
Phenotype and Natural History of ELANE and NON ELANE Severe Congenital Neutropenia in Italy: Data from the National Registry	82
ICOS and OX40 Signaling Optimization Improves CAR-T Cell Persistence in Preclinical Models	81
Clinical Features and Prognosis of Double Primary Malignant Neoplasms in Patients with Non-Hodgkin Lymphoma	80
Relative Telomeric Length of Bone Marrow Cells at Diagnosis and Its Association with Minimal Residual Disease in Juvenile Acute Lymphoblastic Leukemia	80
Anti CD19 CAR-T Cell Therapy Can Clear Minimal Residual Disease in Bone Marrow of Patients with Relapsed or Refractory B Cell Non-Hodgkin's Lymphomas	80
A Rare Case of Spontaneous Tumor Lysis Syndrome As a Consequence of Forgone Treatment in Multiple Myeloma	80
Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis	80
Impact of HLA-B Leader Mismatching on Outcomes after Haploidentical Transplantation with Antithymocyte Globulin	79
The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis	79
Single-Cell Multi-Omic and Spatial Analysis of Nodal B Cell Non-Hodgkin Lymphomas Reveals Plasticity in B Cell Maturation As a Driver of Intratumor Heterogeneity	79
A Single-Center Study of Patients with Isolated Acquired Clotting Factors Deficiency: Clinical Features, Treatments and Prognosis	78
Effect of Hydroxyurea on Patient with High Fetal Hemoglobin Expression	78
Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice	77
Benchmarking Paediatric Sickle Cell Care in Australia	76
Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions	76
Early Versus Late Treatment with Ruxolitinib in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: A Post Hoc Analysis from the Randomized Phase 3 REACH2 Study	75
EFS24 Failure, BRD4 Expression, and TP53 Are Linked to Reduced CDKN1A Expression in DLBCL and May be Targeted By Single-Agent Protac ARV-825 or in Synergistic Combination with the CDK4/6 Inhibitor Abe	75
Concerns about Prognostic Meaning of Quantitative PET Analysis in Classical Hodgkin Lymphoma	75
Targeting Cell Adhesion Molecules in IDH Mutant Myeloid Malignances	74
Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy	74
AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance	73
Shear Stress Promotes Platelet Surface Desialylation, Platelet Count Drop, and Microvesiculation: Do Platelets Need to be Sugar-Coated?	72
Protease Activated Receptor-1 (PAR-1) Inhibition By Parmodulin 2, but Not Vorapaxar, Protects Sickle Cell Mice from Heme-Induced Acute Chest Syndrome	72
A Novel Ptpn11E76K/Npm1cA Murine Model of AML Identifies a Unique Immune Population Relevant to Human Disease	71
Immune Profiling of MM Microenvironment at Single-Cell Resolution	71
Prospective Study of the Usefulness of Liquid Biopsy in Patients with Unknown Fever Suspected of Malignant Lymphoma	71
A Mixed Methods Study to Examine the Influence of Structural Racism on Treatment in Acute Myeloid Leukemia	71
Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study	71
Long Term Follow up of Elderly Patients with Classical Hodgkin's Lymphoma: An Analysis of the Texas Cancer Registry	71
Chronic Myeloid Leukemia Failed Second Generation Tyrosine Kinase Inhibitor Patients' Molecular Interrogation Using Next Generation Sequencing	70
Older Age and Neutrophil-to-Lymphocyte Ratio (NLR) Are Predictors of Illness Severity and COVID-Related Mortality in a Multiethnic Urban Cohort of Hematologic Neoplasms Patients: An Updated Analysis	70
Venetoclax Rapidly and Strongly Enhances the Phospholipase C Response to Azacitidine Therapy in Myelodysplastic Syndromes	70
Training and Validation Cohorts for Predicting the Impact of High Molecular Risk Mutations after Allogeneic Stem Cell Transplantation in Myelofibrosis	70
Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study	69
Blood. 2023;142(22) and 142(25).	69
Impact of Publicly Reported Center Specific Analysis on Patient Selection Practices for Hematopoietic Stem Cell Transplantation	67
Early Onset of Smoldering Disease Correlates with Rapid Progression to Symptomatic Multiple Myeloma	67
Predicting Platelet Age Using Artificial Intelligence Techniques	67
Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients	67
Core transcription balancing erythropoiesis	67
Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphom	67
Castleman's Disease:Clinicopathological Characteristics of a Cohort of Hispanic Patients	67
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre Study	67
Characteristics and Clinical Outcomes of Patients with Acute Myeloid Leukemia with TP53 Mutations - a Single Center Experience	66
Sting Activation Improves T-Cell Engaging Immunotherapy of Acute Myeloid Leukemia	66
Synthetic Lethal Interactions with IRAK4 Inhibition in Myeloid Malignancies	66
Constructing a Machine Learning-Based Rating Model to Predict the Outcome of GCSF Mobilization of Hematopoietic Stem Cells in Peripheral Blood	65
Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement	65
Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study	65
A Retrospective Study Evaluating the Association of Qualitative and Quantitative Aspects of Vaso-Occlusive Crises (VOC) with Length of Hospital Stay in Children with Sickle Cell Disease Hospitalized f	65
Venous Thromboembolism in Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated on a Pediatric-Inspired Regimen	64
Prospective Evaluation of Patient-Reported Outcome up to 10 Years after Allogeneic Stem Cell Transplantation Using FACT-G/BMT and EORTC-QLQ30 Questionnaires	64
No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis	63
Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients	63
Non-Canonical Double Mutant DNMT3A mutations: Clinical and Biological Significance in Myeloid Neoplasms	63
Telomere Length in Survivors of Childhood Hematologic Malignancies	63
Day 100 Risk Assessment Tool Predicts 1 Year Survival in Allogeneic Hematopoietic Cell Transplant Patients	63
Loss of EFL1 Which Causes a Shwachman-Diamond Syndrome Reduces Cell Proliferation and Alters Transcriptional Profiling during Neutrophil Differentiation	62
Total Hip Arthroplasty in Patients with Sickle Cell Disease: A National Database Study	62
Digital Polymerase Chain Reaction (dPCR) Versus Flow Cytometry (FC), a Validation Study for CAR-T Cell Product Optimal Detection	62
Deciphering VITT’s dangerous code	62
Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2-Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation	62
MiRNA29B Induces Fetal Hemoglobin through Targeting DNMT3 and MYB in Vitro and In Vivo in Preclinical Townes Sickle Cell Mice	62
Caregiver Perspectives on Housing, Finances and Employment Post-Allogeneic Hematopoietic Cell Transplant	61
Neurotropin Alleviates Bortezomib-Induced Neurotoxicity Via Microglial Neuroinflammation	61
Treatment of Acute Lymphoblastic Leukemia with PDT Regimen Improves the Prognosis of Newly Diagnosed Central Nervous System Leukemia	61
Genome-Wide Methylome and Transcriptome Profiling of Acute Myeloid Leukemia Derived Bone Marrow Mesenchymal Cells Identify Age Group Specific Biological Pathway Dysregulation in the Bone Marrow Microe	61
Risk of Infections in Multiple Myeloma in the Era of Novel Agents, a Population-Based Study Based on 8672 Multiple Myeloma Patients Diagnosed 2008-2021 from the Swedish Myeloma Registry	61
Association of Hypometilating Agents (HMA) + Venetoclax (VEN) in the Therapy of Acute Myeloid Leukemias Evolved from Myelodysplastic Syndromes (AML-MDS) Already Treated with Azacytidine	61
Evaluation of Immune Reconstitution in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Cevostamab in Phase I Study GO39775	61
Distinct Immune and Molecular Profiles of Hepatitis-Associated Aplastic Anemia	60

Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes	60
Implementing Quality Improvement to Morbidity and Mortality Conferences: Focusing on Action Plans By Closing the Loops with Timely Follow Ups	60
Targeting Sumoylation Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment	60
Influence of Pre-Transplant Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation	60
Fetal Hemoglobin Decrease during Voxelotor Treatment	60
Exploring Regional Challenges and Solutions to Appropriate and Equitable Care for Patients with Chronic Lymphocytic Leukemia	59
Analysis of CD58 As a Predictive Marker of Morphologic Response to Inotuzumab Ozogamicin in Patients with B-Cell Acute Lymphoblastic Leukemia	59
Disease Monitoring in Acute Myeloid Leukemia with CLEC2A qRT-PCR	59
Efficacy of Regular Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate in Reducing Nose Bleeds in Children and Adults with Von Willebrand Disease	58
Renal Sub-Study (GEM-KyCyDex): Cystatin C Improves the Proficiency of Creatinine Alone in the Detection and Management of Myeloma-Related Renal Impairment	58
Prediction Modeling of CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma Using Artificial Neural Networks on Tumor Vascular Phenotype	58
Routine Computed Tomography before Pediatric Hematopoietic Stem Cell Transplantation and Association with Length of Stay and Early Non-Relapse Mortality	58
C17ORF58 Is Upregulated in Peripheral T-Cell Lymphomas and Encodes a Protein Critical for Survival of PTCL Cells	57
Extended Thromboprophylaxis in Patients Hospitalized with COVID-19 at Time of Discharge from the Hospital Is Not Associated with an Improvement in Quality of Life: Results from the Activ 4c Clinical T	57
The Prognostic Value of Common Cardiovascular Biomarkers in the Survival of Patients with DLBCL	57
Real-World Efficacy and Safety of Letermovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis at a Single Center	57
Myeloid Neoplasia in Patients with Hereditary Hemoglobinopathies and Hemolytic Anemias (HHAs)	57
Identification of Healthy Donor Phenotypic and Functional Signatures That Predict Allogeneic, Hypoimmune CD19-Directed CAR T Cell Potency	56
The DNA Sensor AIM2 Determines B Cell Fate after BCR Activation in Chronic Graft-Vs-Host Disease	56
Hemolysis Induced Induction of Matrix Metalloproteinases in Sickle Cell Disease	56
Epic: A Second Interim Analysis of the Non-Interventional, Observational Multi-Centre Cohort Study of Patients with Chronic Lymphocytic Leukaemia Treated with First-Line Acalabrutinib through the UK E	56
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01	55
Efficacy of Daratumumab in 34 Patients with Newly Diagnosed Multiple Myeloma in Real World Study	55
Identification of a Relapse Signature in t(8;21) Pediatric AML	55
Synergy between Iron Deficiency and Inflammation Adversely Affects Pregnancy	55
Contemporary Multiple Myeloma Treatment Patterns Among HCPs and Concordance with Expert Recommendations: Analysis of an Interactive Online Decision Support Tool	55
Overall Survival in Advanced Stage Mantle Cell Lymphoma after Early Autologous Stem Cell Transplantation with Cisplatin, Etoposide, Cytarabine and Melphalan (PEAM) As a Conditioning Regimen	55
Dysfunctional Stromal Pathways Mark Early Changes within the Bone Marrow Microenvironment in JAK2 V617F-Driven Model of Myeloproliferative Neoplasm	55
When Patients with Plasma Cell Disorders Encountered the Largest Omicron Wave (December 2022) in China: A Real-World Multicenter and Multiregional Study	55
Novel Agents May be Preferable to Standard Chemotherapy in Second-Line for Early Relapsing Follicular Lymphoma (FL) Patients	55
Outcomes of Patients Treated at First Transplant Center in Dubai, UAE	55
Effects of Intermittent Fasting on Patients with Immune Thrombocytopenia (ITP) Receiving TPO-RA : Multicenter Mixed-Design Study	54
May-Thurner Syndrome Should be Explored As a Possible Existing Risk Factor in Pediatric Patients Presenting with Non-Central Venous Line Associated Deep Vein Thrombosis	54
Characteristics and Outcomes of Patients Receiving Sequential Bruton's Tyrosine Kinase Inhibitor (BTKi)/B-Cell Lymphoma 2 Inhibitor (BCL2i) for Treatment of Chronic Lymphocytic Leukemia (CLL) in the R	54
Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment	53
Prognostic Factors Impacting Post-Transplant Outcomes in Adult T-Cell Acute Lymphoblastic Leukemia: A Registry-Based Study By the EBMT Acute Leukemia Working Party	53
Reduced Intensity Condition of ATG Based Haploidentical Hematopoietic Stem Cell Transplantation in Elderly or Unfit Patients	53
Clinical and Molecular Features of Patients with Double/Triple Hit Large B-Cell Lymphoma	53
Advances in Acute Myeloid Leukemia Classification: A Comparative Analysis of Who-HAEM4R, Who-HAEM5, and International Consensus Classification	53
Del(20q) As a Somatic Gene Rescue in Adult Patients: Can Germline Mutations Other Than SBDS be Found in Affected Patients?	53
Derivation of a Risk Prediction Model for Venous Thromboembolism in Adult Patients with Acute Myeloid Leukemia	53
Autologous Hematopoietic Stem Cell Transplantation May Overcome the Adverse Impact of IKZF1 on the Prognosis of B-ALL in CR1 with No Detectable Minimal Residual Disease	53
Outcomes of Incorporating IV Daratumumab for the Treatment of AL Amyloidosis in Real World Patients from a Multicenter Registry in Latin America	53
Cytotoxic Stress Transiently Increases the Contribution of Platelet-Biased Hematopoietic Stem Cells to Platelet Production	53
The Efficacy and Prognosis of Advanced Myelodysplastic Syndrome in Children	53
Scalp Cooling to Prevent Hair Loss in Multiple Myeloma Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation	52
Selected Frailty Testing Can Predict for Risk of Febrile Neutropenia in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplant	52
Score to Guide Donor Choice in Haploidentical Stem Cell Transplant Using Post-Transplant Cyclophosphamide for Patients with Acute Myeloid Leukemia: A Study from the Acute Leukemia Working Party of the	51
Informed Representation of Persons Living with Sickle Cell Disease in the US and Factors That Influence Clinical Trial Participation	51
Clinical Characterization of Hepatic Light Chain Amyloidosis in the Chinese Population: A Single-Center Retrospective Analysis	51
Acquired Von Willebrand Syndrome, Epidemiology, Laboratory Findings and Molecular Alterations on Classic Myeloproliferative Neoplasms in Mexican Population	51
Transplant Associated Thrombotic Microangiopathy: Acomprehensive Review and Local Experience	51
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma Trial Eligibility Criteria: A Real-World Multicenter Study	51
Safety and Efficacy of Autologous HSCT in Nine Patients with AIDS-Related Non-Hodgkin Lymphoma	51
Role of Tubulin Detyrosination in Platelet Biogenesis	51
Determinants and Clinical Impact of Time to Plasma Exchange in Patients with Immune Thrombotic Thrombocytopenic Purpura	51
CS585 Demonstrates Favorable Selectivity and Sustained In Vivo Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor Agonists	51
Sequential Conditioning Regimen with Thiotepa, Clofarabine and Busulfan (TEC/CloB2A2) and Post-Transplant Cyclophosphamide in Adults with Refractory AML: A Retrospective Monocentric Study	51
Assessment of Circulating Retinol Binding Protein-4 Levels in Patients with Compound Heterozygosity for Hb S and β-Thalassemia	51
The Kinetics of FLT3L during Induction Chemotherapy for Pediatric Acute Lymphoblastic Leukemia Suggests a Novel Clinical Diagnostic and Treatment Strategy	50
Primary Pulmonary Diffuse Large B-Cell Lymphoma - a Rare Case Report	50
Increased Environmental Temperature Is an Emerging Health Risk That Correlates with Rates of Acute Lymphoblastic Leukemia in Europe	50
Identifying and Managing Patients with Life-Threatening Hematology Disorders By Doing Telemedicine Inpatient Hematology Consults in Underserved Hospitals	50
Α-Globin Lentiviral Vectors for Hematopoietic Stem Cell Gene Therapy of α-Thalassemia	50
Impact of IV Contrast Exposure during Vaso-Occlusive Crisis on Sickle Cell Disease (SCD)	50
A Single-Center Study of Patients with Isolated Acquired Clotting Factor Deficiency: Clinical Features, Treatments, and Prognosis	49
A Real-World Pharmacovigilance Analysis of Chemotherapy-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia	49
A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma	49
Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL	49
Selinexor in Combination with Azacitidine (AZA) in Patients with Myelodysplastic Syndrome (MDS): A Real-World Retrospective Study	49
Characteristics and Outcomes of Younger Adult Patients (Pts) with Myelodysplastic Syndromes (MDS): A Multicenter Retrospective Study	49
Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy	49
Metabolic Reprogramming By PRDM16 Drives Cytarabine Resistance in Acute Myeloid Leukemia	49
Impact of Survivorship Care Plans (SCP) on Mortality in a Contemporary Cohort of Pediatric Patients Diagnosed with a Blood Cancer	49
Donor T Cell Infusions Limit Novel Immune Checkpoint Therapy in Pancreatic Cancer: Implications for Adoptive T Cell Therapy	49
Age, Gvhd Prophylaxis, and Timing Matter in Thrombotic Microangiopathy after Hematopoietic Cell Therapy- a Secondary CIBMTR Analysis	49
Clonal Trafficking of Individual T Cells between Peripheral Blood and Inflamed Synovial Tissue in Patients with Immune-Mediated Refractory Arthritis	48
Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)	48
Prevalence of Plasma Cell Dyscrasias and Outcomes in Patients Referred for Organ Transplantation	48
Impact of PTPN11 Mutations in De Novo, Secondary and Relapsed/Refractory Acute Myeloid Leukemia	48
Development and Characterization of a Novel Murine Peripheral T-Cell Lymphoma Cell Line Which Closely Mimics Human Disease	48
The Use of Caplacizumab in COVID-19-Related TTP	48
Cd70 Deficiency Impairs CD4 + and CD8 + T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas	48
Assessing Treatment Burden in Pediatric Hemophilia: Validation of the Observer-Reported Child Hemophilia Treatment Experience Measure (Child Hemo-TEM)	47
In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma	47
Quantification of Neutrophil Extracellular Traps (NETs) in Pediatric Patients with COVID-19 and Multisystem Inflammatory Syndrome (MIS-C) through Plasma and Peripheral Smear Analysis	47
Establishing Immunocompetent Leukemia Models to Investigate the Impact of CAR T Cells on the Immune Microenvironment and Bone Marrow Niche	47
Abnormal Global Longitudinal Strain Correlates with Amyloidogenic Light Chain-Induced Cardiac Dysfunction via Direct Myocardial Toxicity in Patients without Significant Amyloid Fibril Deposition	47
High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia	47
CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas	47
Serial HLA-Antibody Testing Identifies Waning Calculated Panel Reactive Antibodies (cPRA) in Platelet Transfusion Refractory Patients with Hematologic Malignancies	47
Targeted Inhibition of Phosphodiesterase (PDE) 4 As a Novel Therapy to Increase Endothelial Cell cAMP and Trigger Weibel Palade Body Exocytosis	47
Association between Race and Social Deprivation in Patients with Hematologic Malignancies	47
A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antith	47
Hemophagocytic Lymphohistiocytosis As an Immune-Related Adverse Events in a Patient with Advanced Lung Adenocarcinoma	47